α7 nicotinic acetylcholine receptor agonism confers neuroprotection through GSK-3β inhibition in a mouse model of intracerebral hemorrhage

Stroke

Volumn 43, Issue 3, 2012, Pages 844-850

  Krafft, Paul R ^a   Altay, Orhan ^a   Rolland, William B ^a   Duris, Kamil ^a   Lekic, Tim ^a   Tang, Jiping ^a   Zhang, John H ^a  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

7 nicotinic acetylcholine receptor; apoptosis; caspase 3; glycogen synthase kinase 3; intracerebral hemorrhage; PHA 282987; PHA 543613

Indexed keywords

4 CHLORO N (3 QUINUCLIDINYL)BENZAMIDE; CASPASE 3; GLYCOGEN SYNTHASE KINASE 3BETA; METHYLLYCACONITINE; N (3 QUINUCLIDINYL)FURO[2,3 C]PYRIDINE 5 CARBOXAMIDE; NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7; NICOTINIC RECEPTOR; PROTEIN KINASE B; UNCLASSIFIED DRUG; WORTMANNIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BEHAVIOR DISORDER; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN WATER; CONTROLLED STUDY; IMMUNOFLUORESCENCE TEST; LIMIT OF QUANTITATION; MALE; MORPHOLOGY; MOUSE; NERVE CELL NECROSIS; NEUROPROTECTION; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STIMULATION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BEHAVIOR, ANIMAL; BENZAMIDES; BICYCLO COMPOUNDS; BICYCLO COMPOUNDS, HETEROCYCLIC; BLOTTING, WESTERN; BODY WATER; BRAIN CHEMISTRY; BRAIN EDEMA; CASPASE 3; FLUORESCENT ANTIBODY TECHNIQUE; GLYCOGEN SYNTHASE KINASE 3; INTRACRANIAL HEMORRHAGES; MALE; MICE; NEURONS; NEUROPROTECTIVE AGENTS; NICOTINIC AGONISTS; PHOSPHATIDYLINOSITOL 3-KINASES; QUINUCLIDINES; RECEPTORS, NICOTINIC; SIGNAL TRANSDUCTION; STROKE; TREATMENT OUTCOME;

EID: 84857644494     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.639989     Document Type: Article

References (33)

1. Jorgensen HS, Nakayama H, Raaschou HO, Olsen TS. Intracerebral hemorrhage versus infarction: stroke severity, risk factors, and prognosis. Ann Neurol. 1995;38:45-50.
2. Lyden PD, Zivin JA. Hemorrhagic transformation after cerebral ischemia: mechanisms and incidence. Cerebrovasc Brain Metab Rev. 1993;5:1-16.
3. Matsushita K, Meng W, Wang X, Asahi M, Asahi K, Moskowitz MA, et al. Evidence for apoptosis after intercerebral hemorrhage in rat striatum. J Cereb Blood Flow Metab. 2000;20:396-404.
4. Aronowski J, Hall CE. New horizons for primary intracerebral hemorrhage treatment: experience from preclinical studies. Neurol Res. 2005;27:268-279.
5. Qureshi AI, Suri MF, Ostrow PT, Kim SH, Ali Z, Shatla AA, et al. Apoptosis as a form of cell death in intracerebral hemorrhage. Neurosurgery. 2003;52:1041-1048.
6. Lightfoot AP, Kew JN, Skidmore J. Alpha7 nicotinic acetylcholine receptor agonists and positive allosteric modulators. Prog Med Chem. 2008;46:131-171.
7. Takada-Takatori Y, Kume T, Sugimoto M, Katsuki H, Sugimoto H, Akaike A. Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade. Neuropharmacology. 2006;51:474-486.
8. Duris K, Manaenko A, Suzuki H, Rolland WB, Krafft PR, Zhang JH. α7 nicotinic acetylcholine receptor agonist pnu-282987 attenuates early brain injury in a perforation model of subarachnoid hemorrhage in rats. Stroke. 2011;42:3530-3536.
9. Shaw S, Bencherif M, Marrero MB. Janus kinase 2, an early target of alpha 7 nicotinic acetylcholine receptor-mediated neuroprotection against a beta-(1-42) amyloid. J Biol Chem. 2002;277:44920-44924.
10. Grimes CA, Jope RS. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol. 2001;65:391-426.
11. Valerio A, Bertolotti P, Delbarba A, Perego C, Dossena M, Ragni M, et al. Glycogen synthase kinase-3 inhibition reduces ischemic cerebral damage, restores impaired mitochondrial biogenesis and prevents ROS production. J Neurochem. 2011;116:1148-1159.
12. Bhat RV, Shanley J, Correll MP, Fieles WE, Keith RA, Scott CW, et al. Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3beta in cellular and animal models of neuronal degeneration. Proc Natl Acad Sci U S A. 2000;97:11074-11079.
13. King TD, Bijur GN, Jope RS. Caspase-3 activation induced by inhibition of mitochondrial complex I is facilitated by glycogen synthase kinase-3beta and attenuated by lithium. Brain Res. 2001;919:106-114.
14. Endo H, Nito C, Kamada H, Yu F, Chan PH. Akt/gsk3beta survival signaling is involved in acute brain injury after subarachnoid hemorrhage in rats. Stroke. 2006;37:2140-2146.
15. Wang J, Fields J, Dore S. The development of an improved preclinical mouse model of intracerebral hemorrhage using double infusion of autologous whole blood. Brain Res. 2008;1222:214-221.
16. Ma Q, Manaenko A, Khatibi NH, Chen W, Zhang JH, Tang J. Vascular adhesion protein-1 inhibition provides antiinflammatory protection after an intracerebral hemorrhagic stroke in mice. J Cereb Blood Flow Metab. 2010;31:881-893.
17. Wishka DG, Walker DP, Yates KM, Reitz SC, Jia S, Myers JK, et al. Discovery of n-[(3r)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5- carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure-activity relationship. J Med Chem. 2006;49:4425-4436.
18. Garcia JH, Wagner S, Liu KF, Hu XJ. Neurological deficit and extent of neuronal necrosis attributable to middle cerebral artery occlusion in rats: statistical validation. Stroke. 1995;26:627-634.
19. Hua Y, Schallert T, Keep RF, Wu J, Hoff JT, Xi G. Behavioral tests after intracerebral hemorrhage in the rat. Stroke. 2002;33:2478-2484.
20. MacLellan CL, Langdon KD, Churchill KP, Granter-Button S, Corbett D. Assessing cognitive function after intracerebral hemorrhage in rats. Behav Brain Res. 2009;198:321-328.
21. Ostrowski RP, Colohan AR, Zhang JH. Mechanisms of hyperbaric oxygen-induced neuroprotection in a rat model of subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2005;25:554-571.
22. Gebel JM, Broderick JP. Intracerebral hemorrhage. Neurol Clin. 2000;18:419-438.
23. Nys GM, van Zandvoort MJ, de Kort PL, Jansen BP, de Haan EH, Kappelle LJ. Cognitive disorders in acute stroke: prevalence and clinical determinants. Cerebrovasc Dis. 2007;23:408-416.
24. Deacon RM, Rawlins JN. T-maze alternation in the rodent. Nat Protoc. 2006;1:7-12.
25. Xi G, Keep RF, Hoff JT. Mechanisms of brain injury after intracerebral haemorrhage. Lancet Neurol. 2006;5:53-63.
26. Zazulia AR, Diringer MN, Derdeyn CP, Powers WJ. Progression of mass effect after intracerebral hemorrhage. Stroke. 1999;30:1167-1173.
27. Toyohara J, Hashimoto K. Alpha7 nicotinic receptor agonists: potential therapeutic drugs for treatment of cognitive impairments in schizophrenia and Alzheimer's disease. Open Med Chem J. 2010;4:37-56.
28. Ward JM, Cockcroft VB, Lunt GG, Smillie FS, Wonnacott S. Methyllycaconitine: a selective probe for neuronal alpha-bungarotoxin binding sites. FEBS Lett. 1990;270:45-48.
29. de Jonge WJ, Ulloa L. The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation. Br J Pharmacol. 2007;151:915-929.
30. Marrero MB, Bencherif M, Lippiello PM, Lucas R. Application of alpha7 nicotinic acetylcholine receptor agonists in inflammatory diseases: an overview. Pharm Res. 2011;28:413-416.
31. Wang J. Preclinical and clinical research on inflammation after intracerebral hemorrhage. Prog Neurobiol. 2010;92:463-477.
32. Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science. 2004;303:1483-1487.
33. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. Beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J. 1997;16:3797-3804.